Peter Soelkner

An architectural wonder teaches the biopharmaceutical industry a valuable lesson in project management.

In today's high-cost, highly competitive drug development environment, where complex compounds require sophisticated technology and great expertise, small biotech companies find themselves particularly vulnerable to risk during the early clinical phases. A strategy planned in concert with a contract development and manufacturing organization (CDMO) is often the key to properly allocating resources, creating a top-notch project management team, satisfying regulatory authorities, and advancing the compound to later-phase development.

Knowing in advance what you need can make a huge difference in a sponsor company's success.

Biotech companies will have a much better shot at success with a project management plan and team in place from the very outset